HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lorenzo Galluzzi Selected Research

Antineoplastic Agents (Antineoplastics)

1/2022Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.
1/2022Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer.
1/2022Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.
1/2021Immunomodulation by targeted anticancer agents.
1/2021Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer.
11/2020Detection of immunogenic cell death and its relevance for cancer therapy.
1/2019Macrophages and Metabolism in the Tumor Microenvironment.
1/2018Modeling Tumor Immunology and Immunotherapy in Mice.
11/2017Immune recognition of irradiated cancer cells.
5/2016STAT3 inhibition for cancer therapy: Cell-autonomous effects only?
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lorenzo Galluzzi Research Topics

Disease

212Neoplasms (Cancer)
04/2022 - 01/2007
18Carcinoma (Carcinomatosis)
01/2022 - 07/2008
18Carcinogenesis
01/2021 - 01/2011
16Breast Neoplasms (Breast Cancer)
01/2021 - 05/2012
13Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2019 - 07/2007
12Melanoma (Melanoma, Malignant)
12/2021 - 01/2014
12Necrosis
01/2017 - 02/2009
9Disease Progression
01/2022 - 05/2012
9Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 02/2008
8Tetraploidy
05/2013 - 12/2007
7Inflammation (Inflammations)
01/2022 - 05/2009
5Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 05/2012
5Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2018 - 02/2008
4Obesity
01/2021 - 09/2013
4Genomic Instability
01/2021 - 07/2010
4Bites and Stings (Sting)
10/2020 - 01/2018
4Leukemia
01/2020 - 11/2012
4Infections
01/2020 - 06/2011
4Starvation
10/2019 - 06/2008
3Ovarian Epithelial Carcinoma
01/2022 - 01/2022
3Triple Negative Breast Neoplasms
01/2021 - 10/2020
3Hypoxia (Hypoxemia)
01/2021 - 06/2008
3Lung Neoplasms (Lung Cancer)
01/2019 - 08/2012
3Prostatic Neoplasms (Prostate Cancer)
10/2013 - 10/2012
2Squamous Cell Carcinoma of Head and Neck
01/2022 - 01/2020
2Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 01/2021
2Reperfusion Injury
01/2021 - 09/2013
2Condylomata Acuminata (Genital Wart)
01/2020 - 09/2012
2Actinic Keratosis
01/2020 - 09/2012

Drug/Important Bio-Agent (IBA)

32Antineoplastic Agents (Antineoplastics)IBA
01/2022 - 01/2011
25Immune Checkpoint InhibitorsIBA
01/2022 - 01/2017
25AntigensIBA
01/2020 - 10/2010
23VaccinesIBA
01/2022 - 03/2012
18Proteins (Proteins, Gene)FDA Link
01/2021 - 07/2008
16DNA (Deoxyribonucleic Acid)IBA
01/2020 - 11/2007
11Monoclonal AntibodiesIBA
01/2021 - 01/2012
10Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2018
10CalreticulinIBA
01/2021 - 12/2009
10CytokinesIBA
01/2021 - 07/2012
10Adenosine Triphosphate (ATP)IBA
01/2021 - 06/2008
10Cisplatin (Platino)FDA LinkGeneric
10/2014 - 12/2007
9Phosphotransferases (Kinase)IBA
01/2017 - 07/2008
8AnthracyclinesIBA
01/2021 - 10/2010
8Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2021 - 03/2012
8Peptides (Polypeptides)IBA
01/2021 - 12/2012
8Therapeutic UsesIBA
01/2021 - 08/2012
8Toll-Like Receptor AgonistsIBA
01/2018 - 08/2012
6Pattern Recognition ReceptorsIBA
01/2022 - 02/2010
6LigandsIBA
10/2020 - 10/2010
6Erlotinib Hydrochloride (CP 358,774)FDA Link
09/2013 - 07/2007
5Hormones (Hormone)IBA
01/2021 - 10/2012
5Cytostatic AgentsIBA
01/2021 - 12/2015
5Imiquimod (Aldara)FDA LinkGeneric
01/2020 - 08/2012
5ErbB Receptors (EGF Receptor)IBA
09/2013 - 07/2007
4EpitopesIBA
01/2022 - 01/2018
4PlatinumIBA
01/2022 - 01/2020
4CarcinogensIBA
01/2021 - 09/2012
4Phenobarbital (Luminal)FDA Link
01/2021 - 01/2020
4Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2020 - 03/2012
4Interferon Type IIBA
10/2020 - 01/2019
4InterleukinsIBA
01/2020 - 03/2010
4Pharmaceutical PreparationsIBA
11/2019 - 01/2014
4EnzymesIBA
01/2019 - 12/2011
4Biological ProductsIBA
01/2019 - 07/2012
4Doxorubicin (Adriamycin)FDA LinkGeneric
01/2014 - 03/2012
3InterferonsIBA
01/2022 - 01/2020
3Chimeric Antigen ReceptorsIBA
01/2021 - 11/2015
3Neoplasm Antigens (Tumor Antigens)IBA
01/2021 - 03/2011
3Cyclin-Dependent Kinase 4IBA
01/2021 - 11/2020
3Toll-Like Receptors (Toll-Like Receptor)IBA
01/2020 - 08/2012
3HMGB1 Protein (HMG1)IBA
01/2019 - 03/2012
3RNA (Ribonucleic Acid)IBA
01/2019 - 01/2017
3Formaldehyde (Formol)FDA Link
01/2018 - 08/2012
3Protein Subunit VaccinesIBA
04/2015 - 12/2012
3Vitamin B 6IBA
10/2014 - 08/2012
3Mitoxantrone (Novantrone)FDA LinkGeneric
01/2014 - 03/2012
3Gefitinib (Iressa)FDA Link
09/2013 - 12/2008
3Digoxin (Digitek)FDA LinkGeneric
02/2013 - 07/2012
3Cytotoxins (Cytolysins)IBA
08/2012 - 10/2010
3Sirolimus (Rapamycin)FDA Link
01/2012 - 06/2008
2S-1,2-dichlorovinyl-N-acetylcysteineIBA
01/2022 - 01/2021
2cyclic guanosine monophosphate-adenosine monophosphateIBA
01/2022 - 01/2020
2palbociclibIBA
01/2021 - 11/2020
2CarbohydratesIBA
01/2021 - 01/2018
2Serine (L-Serine)FDA Link
01/2021 - 01/2021
2ChromatinIBA
01/2021 - 01/2013
2Death Domain ReceptorsIBA
01/2021 - 10/2010
2Niacinamide (Nicotinamide)FDA LinkGeneric
01/2021 - 01/2020
2Cell Cycle ProteinsIBA
11/2020 - 01/2020
2AntibodiesIBA
10/2020 - 01/2012
2Mitochondrial DNA (mtDNA)IBA
10/2020 - 01/2005
2theasinensin AIBA
01/2020 - 01/2019
2Double-Stranded RNA (RNA, Double Stranded)IBA
01/2020 - 08/2012
2Bortezomib (Velcade)FDA Link
01/2020 - 04/2015
2Diazepam Binding InhibitorIBA
12/2019 - 10/2019

Therapy/Procedure

89Therapeutics
01/2022 - 07/2008
36Immunotherapy
01/2021 - 09/2012
30Drug Therapy (Chemotherapy)
01/2022 - 01/2007
28Radiotherapy
04/2022 - 12/2007
3Oncolytic Virotherapy
02/2016 - 06/2013